About Event

With numerous clinical candidates demonstrating genuine viability in targeting epigenetic regulators in multiple disease indications, join the Epigenetic Therapeutic Targets Summit – the only virtual summit dedicated to the clinical translation and optimization of therapeutic candidates targeting epigenetic mechanisms of gene expression.

Participate in cross-disciplinary discussions that are transforming epigenetic strategies into the best and first in class approaches for patients with an unmet clinical need. Download the full event guide to learn more.

6 unmissable highlights from this year’s event: 

  1. Targeting cancer with first-in-class inhibitors of the RNA m6A methyltransferase METTL3 with STORM therapeutics.
  2. Chromatin-modifying and RNA-modifying Enzyme Inhibitors as Precision Cancer Therapeutics with Accent Therapeutics.
  3. Overcoming Therapy Resistance to Cancer Immune Therapy, what is the role of epigenetic modulators with 4SC.
  4. Looking at the case of the first-in-class EZH2 inhibitor, Tazemetostat, which received accelerated approval in January 2020 with Epizyme.
  5. Selective Bromodomain Inhibition with the Bromodomain and Extraterminal Domain Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study with Resverlogix Corp.
  6. Targeting SMARCA4-mutant lung cancers through selective, chemically-induced degradation of SMARCA2 with Genentech.

Join us for all of this and more at the Virtual Epigenetic Therapeutic Targets – where the next generation of treatments will be born!